KRAS G12C /TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma - Frost - Translational Lung Cancer Research

Source : https://dx.doi.org/10.21037/tlcr-20-958

Pembrolizumab monotherapy is a highly effective standard-of-care in metastatic, programmed death ligand 1 positive (PD-L1 ≥50%) non-small cell lung cancer (NSCLC) ( 1, 2). However, predictive biomarkers distinguishing long-term responders...

The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33652262/

doi: 10.1016/j.ctrv.2021.102169. Online ahead of print. 1 European Institute of Oncology IRCCS, Milan, Italy; University of Milan, Milan, Italy. 2 European Institute of Oncology IRCCS, Milan, Italy. 3 European Institute...

A case of bilateral invasive mucinous adenocarcinoma of the lung with severe productive cough and dyspnea successfully treated with palliative lung lobectomy

Source : https://doi.org/10.1016/j.rmcr.2021.101368

Update: KRAS Inhibition in Cancer Management

Source : https://hal.archives-ouvertes.fr/hal-03141527/document

KRAS G12C-mutant non-small-cell lung cancer: biology, developmental therapeutics, and molecular testing

Source : https://doi.org/10.1016/j.jmoldx.2021.02.002